Consolidated Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7546761

Concept As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
As at
2022-06-30
2022-01-01 to
2022-06-30
As at
2021-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-362,953,000 JPY
-113,934,000 JPY
Depreciation
15,398,000 JPY
21,568,000 JPY
Interest expenses
4,987,000 JPY
2,735,000 JPY
Foreign exchange losses (gains)
0 JPY
4,000 JPY
Decrease (increase) in trade receivables
12,414,000 JPY
54,895,000 JPY
Subtotal
-339,024,000 JPY
-85,071,000 JPY
Income taxes paid
-2,441,000 JPY
-2,009,000 JPY
Decrease (increase) in inventories
-615,000 JPY
25,721,000 JPY
Net cash provided by (used in) operating activities
-315,940,000 JPY
-43,463,000 JPY
Increase (decrease) in trade payables
1,187,000 JPY
-7,326,000 JPY
Other, net
-18,939,000 JPY
-226,000 JPY
Interest paid
-4,758,000 JPY
-2,638,000 JPY
Cash flows from investing activities
Payments into time deposits
JPY
-100,000,000 JPY
Purchase of property, plant and equipment
-11,347,000 JPY
-153,827,000 JPY
Net cash provided by (used in) investing activities
-11,347,000 JPY
-260,726,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
5,450,000 JPY
114,450,000 JPY
Proceeds from long-term borrowings
JPY
90,000,000 JPY
Net increase (decrease) in short-term borrowings
-4,736,000 JPY
143,783,000 JPY
Repayments of long-term borrowings
-54,132,000 JPY
-22,438,000 JPY
Net cash provided by (used in) financing activities
-53,418,000 JPY
319,145,000 JPY
Net increase (decrease) in cash and cash equivalents
-380,706,000 JPY
14,955,000 JPY
Cash and cash equivalents
3,056,601,000 JPY
3,437,307,000 JPY
1,627,996,000 JPY
1,613,040,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.